BNGO — Bionano Genomics, Inc.

Bionano (BNGO) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $6.7 million, a 4% increase year-over-year, aligning with guidance of $6.5 million to $6.7 million.
• Flow Cells Sold: 8,178 units, up 17% year-over-year, marking a record for Q1.
• Consumable Revenue: $3.9 million, up 20% year-over-year.
• Software Revenue: $1.2 million, down 40% year-over-year due to a large prior-year sale.
• Other Revenue: $1.6 million, up 36% year-over-year.
• Gross Margin: Adjusted gross margin improved to 49%, up from 46% in Q1 2025.
• Operating Expenses: Increased to $9.1 million from $8.5 million in Q1 2025.
• Cash Position: $24.7 million in cash and equivalents, with $10.3 million restricted.
• Debt: Expected to fully retire senior secured convertible debt in May 2026.

2. Strategic Updates and Business Highlights

• Leadership Transition: Dr. Al Luderer has stepped in as Interim CEO, focusing on business continuity and long-term leadership transition.
• Strategic Focus: Shift towards profitable growth with existing users, emphasizing routine user acquisition and OGM (optical genome mapping) utilization.
• Reimbursement Milestones: Significant increases in reimbursement rates for OGM, including a 47% increase for hematologic malignancies and a new CPT code for constitutional genetic disorders.
• Publication Momentum: 28 new publications on OGM's utility for rare diseases, a 56% increase from Q1 2025, indicating growing acceptance and application in clinical settings.
• OGM Adoption: Positive feedback on software upgrades, enhancing throughput and usability for existing customers.

3. Forward Guidance and Outlook

• Q2 2026 Revenue Guidance: $7.5 million to $7.8 million, representing 12% to 16% growth over Q2 2025.
• Full Year 2026 Revenue Guidance: Reaffirmed at $30 million to $33 million, indicating growth of 5% to 16% over 2025.
• Cash runway expected to extend into 2027.

4. Bad News, Challenges, or Points of Concern

• Operating Cash Flow: The company does not expect to reach cash flow breakeven by the end of 2026, with potential for breakeven pushed to late 2027.
• Software Revenue Decline: A significant drop in software revenue due to prior-year sales affecting current demand.
• Operating Expenses: Rising operating expenses may impact profitability despite improved gross margins.
• Supply Constraints: Although flow cell production is improving, past constraints could affect future sales momentum.

5. Notable Q&A Insights

• Cash Flow Breakeven: Management clarified that achieving cash flow breakeven by the end of 2026 is not anticipated, with efforts focused on reducing burn rates.
• Growth Catalysts: Reimbursement improvements and debt elimination are seen as significant catalysts for future growth, alongside ongoing publications supporting OGM adoption.
• User-Driven Transformation: The transition from company-led initiatives to user-driven standards and practices is highlighted as a critical change in the company's trajectory.

This summary encapsulates the key points from Bionano's Q1 2026 earnings call, providing a balanced view of the company's performance, strategic direction, and challenges ahead.